The effect of pharmacist‐led interventions on the management and outcomes in chronic kidney disease (CKD): A systematic review and meta‐analysis protocol

Author:

Ardavani Ashkon1ORCID,Curtis Ffion1,Khunti Kamlesh1,Wilkinson Thomas J.1ORCID

Affiliation:

1. NIHR Applied Research Collaboration East Midlands (ARC‐EM), Leicester Diabetes Center University of Leicester Leicester UK

Abstract

AbstractBackground and AimsChronic kidney disease (CKD) is a progressive condition that results in a decline in kidney function over time. There are several conditions that increase the likelihood of developing CKD, particularly diabetes and hypertension. CKD increases the risk of mortality and has a detrimental impact on quality of life (QoL). Strategies for managing CKD include controlling cardiovascular risk factors and treating complications of CKD. There is an ever‐increasing role of pharmacists in managing CKD, from the optimization of risk factors to patient education. However, currently, there is a lack of data on the effect pharmacist‐led interventions have on the clinical, economic, and humanistic outcomes.MethodsThis protocol, in adherence to PRISMA‐P (Preferred Reporting Items for Systematic review and Meta‐Analysis Protocols) standards, describes a prospective systematic review and meta‐analysis of randomized controlled trials, where any intervention led by a pharmacist in CKD is used. Comparison groups will consist of usual care or non‐pharmacist‐led interventions. Literature searches will be conducted in the following databases: MEDLINE, Scopus, and Web of Science. Data pertaining to clinical (e.g., mortality), economic (e.g., healthcare‐associated costs), and humanistic (e.g., QoL) outcomes will be extracted. Risk of bias will be assessed using the United States National Heart Lung and Blood Institute quality assessment tool for controlled intervention studies. A meta‐analysis will be conducted to synthesize appropriate comparable outcomes.ResultsThe findings of this review will be published in a peer‐reviewed journal, where the results will be presented in lay language with appropriate infographics online and via social media.ConclusionThe findings of this review can identify gaps in the literature concerning optimizing pharmacist‐led interventions in improving outcomes. In addition, this review will establish the importance of pharmacists in managing CKD patients, and whether this may result in their increased incorporation in multidisciplinary teams.

Funder

University of Leicester

Publisher

Wiley

Subject

General Medicine

Reference32 articles.

1. Chronic kidney disease

2. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease;Kidney Disease: Improving Global, Outcomes (KDIGO) CKD Work Group;Kidney Int Suppl,2013

3. NICE | The National Institute for Health and Care Excellence. Recommendations | Chronic kidney disease: assessment and management | Guidance | NICE [Internet]. 2021 [cited2022Mar 21]. Available from:https://www.nice.org.uk/guidance/ng203/chapter/Recommendations

4. Chronic Kidney Disease

5. Chronic Kidney Disease and the Aging Population

Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3